OncoOne

Fighting Cancer And Inflammation With Unprecedented Precision

About this Event

The world-class antibody engineers at OncoOne are creating monoclonal antibodies based on two platform technologies to treat a wide range of diseases with exacting specificity and precision.

For decades researchers suspected that Macrophage Migration Inhibitory Factor (MIF) was a critical target for cancer and autoimmune therapeutics. But after 20 years of research and more than 3,000 publications, little was understood about the ubiquitous expression of MIF in healthy and diseased tissue. It wasn’t until the leaders of OncoOne discovered an oxidized subvariant, oxMIF, were they able to unleash its potential.

OxMIF is generated only in diseased tissue. This has allowed the world-class antibody engineers at OncoOne to create monoclonal antibodies (mAbs) that treat diseases with exacting specificity and precision.

It is hard to overstate the potential of this discovery. Targeting oxMIF creates a diverse pipeline of treatment options for several solid tumor cancers with high unmet medical need, as well as inflammatory diseases including rheumatoid arthritis and nephritis.

Their lead program, ON203, is a therapeutic mAb that’s IND-ready for clinical trials targeting colorectal and lung cancer, with the potential to expand to other tumor types. Clinical trials are scheduled to begin in the U.S. in early 2025.

Watch this event with OncoOne Co-founder and CEO, Randolf Kerschbaumer, to hear more about how the discovery of oxMIF has the potential to save millions of lives.

Video On Demand

– Recorded

October 16

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.